Manning & Napier Advisors LLC Buys 3,278 Shares of Becton, Dickinson and Company $BDX

Manning & Napier Advisors LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.5% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 34,426 shares of the medical instruments supplier’s stock after buying an additional 3,278 shares during the period. Manning & Napier Advisors LLC’s holdings in Becton, Dickinson and Company were worth $5,343,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vega Investment Solutions purchased a new stake in Becton, Dickinson and Company during the second quarter valued at about $182,000. Aberdeen Wealth Management LLC bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter valued at about $44,000. Cullen Capital Management LLC raised its position in Becton, Dickinson and Company by 13.1% in the 2nd quarter. Cullen Capital Management LLC now owns 824,720 shares of the medical instruments supplier’s stock worth $124,805,000 after purchasing an additional 95,559 shares during the period. Allstate Corp boosted its position in Becton, Dickinson and Company by 4.8% during the second quarter. Allstate Corp now owns 36,187 shares of the medical instruments supplier’s stock valued at $5,476,000 after buying an additional 1,654 shares during the period. Finally, Cibc World Market Inc. grew its stake in shares of Becton, Dickinson and Company by 938.6% during the second quarter. Cibc World Market Inc. now owns 62,834 shares of the medical instruments supplier’s stock valued at $9,509,000 after buying an additional 56,784 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 0.7%

NYSE:BDX opened at $190.58 on Tuesday. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The firm has a market capitalization of $52.51 billion, a P/E ratio of 57.40, a PEG ratio of 13.53 and a beta of 0.19. The company’s 50-day simple moving average is $162.48 and its 200 day simple moving average is $160.73.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Royal Bank Of Canada boosted their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research report on Thursday, August 13th. Jefferies Financial Group restated a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Barclays upped their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Finally, Wells Fargo & Company raised their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $185.67.

Insider Activity

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,704 shares of company stock worth $1,963,618 over the last quarter. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.